MedTrace Logo

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

NCT03172455 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-10-05

No results posted yet for this study

Summary

An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation.

This Program is available for female and male who are recipients of allogenic HSCT and who have been newly diagnosed with acute GvHD.

Conditions

  • Acute-graft-versus-host Disease
  • Steroid Refractory Acute Graft Versus Host Disease
  • Graft-versus-host-disease
  • Graft Vs Host Disease
  • Alpha 1-Antitrypsin Deficiency
  • Alpha-1 Proteinase Inhibitor
  • Alpha-1 Protease Inhibitor Deficiency
  • Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant

Interventions

DRUG

Glassia

Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)

Sponsors & Collaborators

  • Kamada, Ltd.

    collaborator INDUSTRY

  • Impatients N.V. trading as myTomorrows

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03172455 on ClinicalTrials.gov